Clinical trials: Steroid Refractory GVHD
Graft Versus Host Disease
Identification of Novel Targetable Kinases in SR-a GvHD
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Trial name
- NCT04342442
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Graft vs Host Disease
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease
Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties. Following a bone marrow/peripheral blood stem cell transplant, a proportion of patients develop a condition called 'graft versus host disease'…
- Trial name
- NCT00314483
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- India
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Chronic Graft vs Host Disease
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
- Trial name
- GVHD-TReG (NCT03683498)
- Testing
- Regulatory T-cell enriched infusion
- Where
- Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Graft vs Host Disease
A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease
Phase 1/2 clinical study for the treatment of steroid-refractory chronic graft versus host disease after an allogeneic transplant of hematopoietic progenitors with donor CliniMACS-selected regulatory T cells
- Trial name
- TREGeneration (NCT02385019)
- Testing
- Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
- Where
- 3 sites in Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes